Navigation Links
Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia
Date:6/14/2010

ult patients with B precursor acute lymphoblastic leukemia.  Enrolled patients had sub-microscopic evidence of leukemic cells in the bone marrow following treatment with front-line chemotherapy, so called minimal residual disease (MRD). The primary endpoint of the study was MRD response. Key secondary endpoints included time to hematological relapse, time to molecular relapse and overall incidence and severity of adverse events.  Patients received 15 micrograms per meter squared per day of blinatumomab for 28 days followed by two weeks off therapy over a six week treatment cycle.  

Phase 2 Results

21 patients were treated in this study.  Of 20 evaluable patients, 80% (16 out of 20) achieved a complete MRD response. Among the 13 non-transplanted patients, there were eight patients with non-Ph+ or t(4;11) disease. For these eight patients the median time to hematological relapse has not been reached at a median follow-up of 480 days.  For a similar group of patients with MRD positive disease treated with chemotherapy by the German Multicenter Adult ALL Study Group (GMALL), a median time to hematological relapse of approximately 200 days from diagnosis has been reported(1).

Eight of the patients in the study received an allogeneic transplant after blinatumomab treatment, all of whom are alive and in remission, ranging up to 21 months.  Overall, blinatumomab was well-tolerated. The most common adverse events (any grade) were fever, decreases of immunoglobulins, and headache.  Two patients discontinued treatment due to adverse events; seizure and syncope, respectively, with both events being completely reversible.  

"Historical experience suggests that there is a high mortality rate among patients with ALL who receive a stem cell transplant," said Dr. Topp. "Notably, no deaths or relapses have been
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
2. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
4. Newly Updated Pharmacy State Law Compendium Available
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
6. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
7. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
8. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
9. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
10. ORTHO EVRA(R) Prescribing Information Updated
11. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015 Magnaquest, a ... data and cloud computing operators has signed a ... giant for Internet of Things (IoT) related initiative. ... on subscription model.      (Logo: ... striving for business innovations to make healthcare services ...
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 ... it will release its second quarter 2015 financial results ... 2015.   In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/30/2015)... edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates 50 years, ... the success of the prescription drug benefit, commonly referred to as Part D. ... videos here: http://onphr.ma/1INp9qQ ... ... More ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... in Combination with Chemotherapy, FREMONT, Calif. ... pharmaceutical company discovering and developing novel,RNA interference ... Research published results on efficacy of siRNA ... lung cancer (NSCLC) in,the edition dated October ...
... Pivotal Data Show Prophylaxis Treatment with Kogenate FS ... in Children with No Pre-Existing,Joint Damage, BERKELEY, ... that the U.S. Food and Drug Administration (FDA) ... to reduce the frequency of bleeding episodes and ...
Cached Medicine Technology:Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark ... for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The ... post-acute care providers understand the benefits of using medication management technologies . ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Hospital's Karmanos Center for Natural Birth . The Karmanos Center for ... safe natural childbirth experience. With nurses and caregivers that are trained in holistic ...
(Date:7/31/2015)... ... July 31, 2015 , ... New Energy Works Timberframers ... Amphitheater in McMinnville, Oregon August 15th, 2015 from 9am – 12pm. Timber frame ... important day for the entire community as the culmination of months of effort, planning, ...
(Date:7/31/2015)... ... July 31, 2015 , ... An article entitled ... talked about a woman’s unfortunate experience having cosmetic skin procedures done by a ... resulted in blistering, swelling, bruising, and pain. This woman’s experience is only one ...
(Date:7/31/2015)... ... July 31, 2015 , ... In the most recent testosterone ... in the Northern District of Illinois, Androgel testosterone attorneys report that a “Mini Status ... entry was made recording the minutes of the status conference, which was held that ...
Breaking Medicine News(10 mins):Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4
... Joins Thousands of Participants in Inspirational Closing Ceremony; ... Breast Cancer Organizations, WASHINGTON, May 4 ... Reese Witherspoon was a special guest at the,sixth ... this weekend,cheering on and joining walkers on their ...
... to an expanding waist line, weight gain and a tendency ... of a study published today in the journal Nature Genetics. ... is significantly more common in those with Indian Asian than ... Heart Foundation, could lead to better ways of treating obesity. ...
... knowledge gap, experts say , , SUNDAY, May 4 (HealthDay ... surprisingly low knowledge of child development, including basic concepts ... should act, a new study finds. , For instance, ... 1-year-olds can,t tell the difference between right and wrong, ...
... Study shows only 49% intended to do so if child ... News) -- New research shows that only half of American ... papillomavirus (HPV) if the girls are under the age of ... which is sexually transmitted, is the primary cause of cervical ...
... assumptions, children are more vulnerable to the harmful effects ... they are in early childhood, according to a Cincinnati ... 4 at the annual meeting of the Pediatric Academic ... protecting toddlers from lead exposure, our study shows that ...
... U.S. parents have a surprisingly low-level knowledge of ... childs physical, social and emotional growth, according research ... which suggest that such false parenting assumptions can ... kids of much-needed cognitive stimulation, will be presented ...
Cached Medicine News:Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 2Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 3Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 4Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 5Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 6Health News:Gene sequence that can make half of us fatter is discovered 2Health News:One-Third of Parents Lack Facts About Child Development 2Health News:One-Third of Parents Lack Facts About Child Development 3Health News:Many Moms Unwilling to Have Younger Daughters Get HPV Vaccine 2Health News:Many Moms Unwilling to Have Younger Daughters Get HPV Vaccine 3Health News:Children more vulnerable to harmful effects of lead 2Health News:Nearly one-third of US parents don't know what to expect of infants 2
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Manual Table For Slit Lamp...
Medicine Products: